FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 235 filers reported holding FATE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,376,185 | +47.1% | 2,064,238 | +230.2% | 0.00% | +100.0% |
| Q2 2023 | $2,975,290 | +30020.4% | 625,061 | -63.9% | 0.00% | -83.3% |
| Q1 2023 | $9,878 | -65.8% | 1,732,987 | -39.5% | 0.01% | -62.5% |
| Q4 2022 | $28,903 | -99.8% | 2,864,476 | +347.1% | 0.02% | +100.0% |
| Q3 2022 | $14,359,000 | -20.6% | 640,724 | -12.2% | 0.01% | -27.3% |
| Q2 2022 | $18,084,000 | +50.4% | 729,771 | +135.3% | 0.01% | +83.3% |
| Q1 2022 | $12,024,000 | +580.9% | 310,144 | +927.7% | 0.01% | +500.0% |
| Q4 2021 | $1,766,000 | -73.8% | 30,177 | -73.4% | 0.00% | -75.0% |
| Q3 2021 | $6,731,000 | -53.7% | 113,561 | -32.2% | 0.00% | -55.6% |
| Q2 2021 | $14,540,000 | -34.2% | 167,534 | -37.5% | 0.01% | -43.8% |
| Q1 2021 | $22,095,000 | -21.6% | 267,978 | -13.5% | 0.02% | -20.0% |
| Q4 2020 | $28,184,000 | +52.0% | 309,951 | -33.2% | 0.02% | -13.0% |
| Q3 2020 | $18,544,000 | -52.6% | 463,946 | -59.3% | 0.02% | -57.4% |
| Q2 2020 | $39,121,000 | +120.4% | 1,140,235 | +42.7% | 0.05% | +35.0% |
| Q1 2020 | $17,747,000 | -42.4% | 799,035 | -49.3% | 0.04% | +2.6% |
| Q4 2019 | $30,825,000 | -40.8% | 1,575,108 | -53.1% | 0.04% | -52.4% |
| Q3 2019 | $52,105,000 | +26.9% | 3,355,119 | +65.8% | 0.08% | +32.3% |
| Q2 2019 | $41,067,000 | +45.5% | 2,022,985 | +25.9% | 0.06% | +47.6% |
| Q1 2019 | $28,222,000 | +274.3% | 1,606,254 | +173.3% | 0.04% | +250.0% |
| Q4 2018 | $7,539,000 | +190.6% | 587,640 | +269.0% | 0.01% | +300.0% |
| Q3 2018 | $2,594,000 | -66.6% | 159,241 | -76.8% | 0.00% | -70.0% |
| Q2 2018 | $7,770,000 | +275.4% | 685,142 | +102.2% | 0.01% | +233.3% |
| Q4 2017 | $2,070,000 | +1400.0% | 338,799 | +873.6% | 0.00% | – |
| Q3 2017 | $138,000 | -20.7% | 34,800 | -35.1% | 0.00% | – |
| Q2 2017 | $174,000 | -80.5% | 53,614 | -72.6% | 0.00% | -100.0% |
| Q1 2017 | $891,000 | +2244.7% | 195,928 | +1514.4% | 0.00% | – |
| Q3 2016 | $38,000 | -42.4% | 12,136 | -66.9% | 0.00% | – |
| Q1 2016 | $66,000 | -79.4% | 36,697 | -61.5% | 0.00% | -100.0% |
| Q4 2015 | $321,000 | +483.6% | 95,230 | +823.4% | 0.00% | – |
| Q3 2015 | $55,000 | -66.7% | 10,313 | -60.6% | 0.00% | -100.0% |
| Q4 2013 | $165,000 | – | 26,201 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |